RECURSION PHARMACEUTICALS, INC. (RXRX) Form 8-K — Nov 2, 2026

$RXRXForm 8-KItems 2.02, 5.02, 7.01, 9.01Filed Nov 2, 2026, 4:32 PM ET0001601830-26-000144Original filing

Recursion Pharmaceuticals filed an 8-K announcing its Q3 2026 results alongside the appointment of Fred Hassan, a four-decade pharma veteran, as Chair of the Board effective October 31, 2026, expanding the Board to 10 members. The filing highlights strong partnership momentum: Sanofi optioned a potential first-in-class oral immunology candidate, triggering a $10 million milestone and bringing Sanofi inflows to $144 million, with $343 million in potential milestones per program plus double-digit royalties.

Key figures

Guidance: 2026 cash operating expense < $375M; 2027 cash operating expense < $360M; cash runway into 2029
Cash Position: $749M pro forma cash and cash equivalents (Sep 30, 2026, incl. $187.2M net October 2026 financing proceeds)
Proprietary data: 50+ petabytes of proprietary biological data as of Sep 30, 2026
Sanofi milestone: $10M milestone payment triggered by candidate option
Board size change: 9 to 10 members
Sanofi total inflows: $144M upfront and milestone payments to date from Sanofi
October 2026 follow on: $200M oversubscribed financing completed October 16, 2026
Partner inflows to date: $535M+ total partner inflows, $100M+ from 9 milestones in ~2 years
Sanofi potential milestones: $343M potential milestones per program plus double-digit royalties
Genentech potential milestones: >$300M potential milestones per small molecule program plus high single digit royalties

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.